Drugs / HS022
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06107790 | May 2018 → Jan 2022 | HER2 positive breast carcinoma | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06107790 ↗ |